2024
An Updated Simplified Severity Scale for Age-Related Macular Degeneration Incorporating Reticular Pseudodrusen Age-Related Eye Disease Study Report Number 42
Agrón E, Domalpally A, Chen Q, Lu Z, Chew E, Keenan T, Groups A. An Updated Simplified Severity Scale for Age-Related Macular Degeneration Incorporating Reticular Pseudodrusen Age-Related Eye Disease Study Report Number 42. Ophthalmology 2024, 131: 1164-1174. PMID: 38657840, PMCID: PMC11416341, DOI: 10.1016/j.ophtha.2024.04.011.Peer-Reviewed Original ResearchAge-related eye disease studyProgression to late AMDReticular pseudodrusenLate AMDFive-year ratesProgression rateAge-related macular degenerationSeverity ScaleEye Disease StudyClinical trial cohortIncrease prognostic accuracyPost Hoc AnalysisMacular degenerationAREDS2Prognostic accuracyTrial cohortRisk featuresHoc AnalysisRisk categorizationPseudodrusenAge-relatedBaselineDisease StudyRiskExternal validation
2023
Oncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy
Contieri R, Hensley P, Tan W, Grajales V, Bree K, Nogueras-Gonzalez G, Lee B, Navai N, Dinney C, Kamat A. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. European Urology Oncology 2023, 6: 590-596. PMID: 37558542, DOI: 10.1016/j.euo.2023.07.012.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerCancer-specific mortalityBacillus Calmette-GuerinHigh-grade recurrenceHigh-risk non-muscle-invasive bladder cancerOverall survivalBladder cancerEuropean Urological AssociationOncological outcomesNo significant differenceEarly RCPatients treated with bacillus Calmette-GuerinTreated with bacillus Calmette-GuerinNon-muscle invasive bladder cancerIntravesical BCGContemporary cohort of patientsCancer-specific mortality ratesProgression rateBacillus Calmette-Guerin groupEarly radical cystectomyMedian Follow-UpInvasive bladder cancerSignificant differenceCohort of patientsEarly surgical removal
2022
External validation of yonsei nomogram predicting chronic kidney disease development after partial nephrectomy: An international, multicenter study
Raheem A, Landi I, Alowidah I, Capitanio U, Montorsi F, Larcher A, Derweesh I, Ghali F, Mottrie A, Mazzone E, De Naeyer G, Campi R, Sessa F, Carini M, Minervini A, Raman J, Rjepaj C, Kriegmair M, Autorino R, Veccia A, Mir M, Claps F, Choi Y, Ham W, Santok G, Tadifa J, Syling J, Furlan M, Simeone C, Bada M, Celia A, Carrión D, Bazan A, Ruiz C, Malki M, Barber N, Hussain M, Micali S, Puliatti S, Ghaith A, Hagras A, Ghoneem A, Eissa A, Alqahtani A, Rumaih A, Alwahabi A, Alenzi M, Pavan N, Traunero F, Antonelli A, Porcaro A, Illiano E, Costantini E, Rha K. External validation of yonsei nomogram predicting chronic kidney disease development after partial nephrectomy: An international, multicenter study. International Journal Of Urology 2022, 30: 308-317. PMID: 36478459, DOI: 10.1111/iju.15108.Peer-Reviewed Original ResearchConceptsNew-onset CKDCKD stageChronic kidney disease developmentExternal validationCKD stage ICT1 renal massesKidney disease developmentPreoperative eGFRPatient ageConsecutive patientsMulticenter studyTumor sizePartial nephrectomyRenal massesProgression rateGood calibration propertiesStage IProgression probabilityPatientsNomogramIndividual riskCKDDisease developmentEGFRMedian valueApplication of longitudinal item response theory models to modeling Parkinson’s disease progression
Zou H, Aggarwal V, Stebbins G, Müller M, Cedarbaum J, Pedata A, Stephenson D, Simuni T, Luo S. Application of longitudinal item response theory models to modeling Parkinson’s disease progression. CPT Pharmacometrics & Systems Pharmacology 2022, 11: 1382-1392. PMID: 35895005, PMCID: PMC9574723, DOI: 10.1002/psp4.12853.Peer-Reviewed Original ResearchConceptsEarly Parkinson's diseaseParkinson's diseaseDisease progressionProgression rateUnified Parkinson's Disease Rating Scale part 2Stage 1Yahr stage 1Higher baseline severityCommon clinical outcomeLongitudinal disease progressionSlow progression rateParkinson's disease progressionMovement Disorder SocietyStage 2Clinical outcomesMotor signsBaseline severitySlow progressionSum scoreTotal scoreLongitudinal item response theory modelProgressionSeverityPatientsDisease
2021
Alterations of the serum and CSF ferritin levels and the diagnosis and prognosis of amyotrophic lateral sclerosis
Paydarnia P, Mayeli M, Shafie M, Agah E, Hasani S, Jazani M, Sarraf P. Alterations of the serum and CSF ferritin levels and the diagnosis and prognosis of amyotrophic lateral sclerosis. ENeurologicalSci 2021, 25: 100379. PMID: 34869924, PMCID: PMC8626833, DOI: 10.1016/j.ensci.2021.100379.Peer-Reviewed Original ResearchSerum ferritin levelsCSF ferritin levelsFerritin levelsDisease progression rateDisease durationPrognosis of amyotrophic lateral sclerosisDiagnosis of ALCSF of patientsDiagnostic challengePrognostic utilityControl patientsProgression rateALS patientsExclusion criteriaSerumELISA methodPatientsPotential biomarkersAmyotrophic lateral sclerosisCSFALS casesDiseaseDiagnosisLateral sclerosisAlterationsProgression of aortic stenosis in patients with bicuspid aortic valve
Shang M, Kahler‐Quesada A, Mori M, Yousef S, Geirsson A, Vallabhajosyula P. Progression of aortic stenosis in patients with bicuspid aortic valve. Journal Of Cardiac Surgery 2021, 36: 4665-4672. PMID: 34585444, DOI: 10.1111/jocs.16026.Peer-Reviewed Original ResearchConceptsBicuspid aortic valveMmHg/yearModerate aortic stenosisAortic valve replacementAortic stenosisMore rapid progressionAortic valveValve replacementRapid progressionProgression rateStepwise Cox proportional hazards modelValve phenotypeCox proportional hazards modelCommon congenital heart defectTricuspid aortic stenosisMean gradientCongestive heart failureRate of progressionProportional hazards modelCongenital heart defectsBaseline comorbiditiesBaseline echocardiogramComorbid hypertensionEchocardiographic surveillanceHeart failureWarm ischemia time length during on-clamp partial nephrectomy: dose it really matter?
Abdel Raheem A, Alowidah I, Capitanio U, Montorsi F, Larcher A, Derweesh I, Ghali F, Mottrie A, Mazzone E, DE Naeyer G, Campi R, Sessa F, Carini M, Minervini A, Raman J, Rjepaj C, Kriegmair M, Autorino R, Veccia A, Mir M, Claps F, Choi Y, Ham W, Tadifa J, Santok G, Furlan M, Simeone C, Bada M, Celia A, Carrión D, Aguilera Bazan A, Ballesteros Ruiz C, Malki M, Barber N, Hussain M, Micali S, Puliatti S, Alwahabi A, Alqahtani A, Rumaih A, Ghaith A, Ghoneem A, Hagras A, Eissa A, Alenzi M, Pavan N, Traunero F, Antonelli A, Porcaro A, Illiano E, Costantini E, Rha K. Warm ischemia time length during on-clamp partial nephrectomy: dose it really matter? Minerva Urologica E Nefrologica 2021, 74: 194-202. PMID: 34308610, DOI: 10.23736/s2724-6051.21.04466-9.Peer-Reviewed Original ResearchConceptsClamp partial nephrectomyWarm ischemia timePartial nephrectomyEGFR preservationCKD stageEGFR valuesProgression rateGroup IILong-term renal functionGroup ILong-term renal function outcomeUnivariable Cox regression analysisMedian eGFR valueRenal function outcomesInternational cohort studyRenal functional recoveryCox regression analysisML/Regression analysisDisease upgradingEGFR declineEGFR changeCohort studyRenal functionFinal cohort
2019
67 Appraisal of Follow-up Protocols and Outcomes of High Risk Pancreatic Cancer Surveillance Programs: A Systematic Review and Meta-Analysis
Chhoda A, Mukherjee E, Wattamwar K, Kastrinos F, Farrell J. 67 Appraisal of Follow-up Protocols and Outcomes of High Risk Pancreatic Cancer Surveillance Programs: A Systematic Review and Meta-Analysis. The American Journal Of Gastroenterology 2019, 114: s40-s41. DOI: 10.14309/01.ajg.0000589800.17291.ef.Peer-Reviewed Original ResearchHigh-risk individualsCross-sectional imagingEndoscopic ultrasoundPancreatic cancerDiagnostic rateSectional imagingSystematic reviewPt-yrNew lesionsBaseline imagingAdvanced pathologyCumulative progression rateCancer Surveillance ProgramOptimal imaging modalityPre-existing abnormalitiesSignificant differencesOutcomes of interestRandom-effects modelFirst systematic reviewUncontrolled studiesProspective studySubgroup analysisSurveillance protocolHistologic diagnosisProgression rateRECLASSIFICATION OF FUNDUS AUTOFLUORESCENCE PATTERNS SURROUNDING GEOGRAPHIC ATROPHY BASED ON PROGRESSION RATE
Shen LL, Liu F, Nardini HG, Del Priore LV. RECLASSIFICATION OF FUNDUS AUTOFLUORESCENCE PATTERNS SURROUNDING GEOGRAPHIC ATROPHY BASED ON PROGRESSION RATE. Retina 2019, Publish Ahead of Print: &na;. PMID: 30829988, DOI: 10.1097/iae.0000000000002480.Peer-Reviewed Original ResearchConceptsGA progression ratesFAF patternsGeographic atrophyProgression rateHorizontal translation factorFundus autofluorescence patternsDifferent entry timesLesion progression ratesFundus autofluorescenceCochrane LibraryClinical trialsAutofluorescence patternsGroup 2Group 1Group 3Group 4Natural historyAtrophyGroupRadius growth rateYearsEMBASEMEDLINEPubMedFrom clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities?
Bewersdorf JP, Ardasheva A, Podoltsev NA, Singh A, Biancon G, Halene S, Zeidan AM. From clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities? Blood Reviews 2019, 37: 100587. PMID: 31400824, DOI: 10.1016/j.blre.2019.100587.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMyeloid neoplasmsClonal hematopoiesisTherapy-related myeloid neoplasmsAnnual progression rateHealthy elderly individualsGenetic testing resultsCardiovascular mortalityHematologic disordersMyeloid leukemiaClinical significanceProgression ratePremalignant stateElderly individualsDiagnostic criteriaPreventive opportunitiesSolid tumorsClinical settingNatural historyFurther studiesPatientsSomatic mutationsRiskHematopoiesisCurrent understandingICUs
2018
Fellow Eye Status Is a Biomarker for the Progression Rate of Geographic Atrophy A Systematic Review and Meta-analysis
Shen LL, Liu F, Grossetta Nardini H, Del Priore LV. Fellow Eye Status Is a Biomarker for the Progression Rate of Geographic Atrophy A Systematic Review and Meta-analysis. Ophthalmology Retina 2018, 3: 305-315. PMID: 31014681, DOI: 10.1016/j.oret.2018.11.013.Peer-Reviewed Original ResearchConceptsAge-related macular degenerationFellow eye statusFellow eyesChoroidal neovascularizationGeographic atrophyProgression rateEye statusPrimary eyesSystematic reviewAdvanced age-related macular degenerationGA enlargement rateHorizontal translation factorA Systematic ReviewGA progression ratesNewcastle-Ottawa ScalePrior clinical studiesDifferent entry timesGA patientsCochrane LibraryClinical trialsClinical studiesEgger's testMacular degenerationStudy qualityBegg's test
2015
Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis
Smith DJ, Combellick J, Jordan AE, Hagan H. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis. International Journal Of Drug Policy 2015, 26: 911-921. PMID: 26298331, PMCID: PMC4577462, DOI: 10.1016/j.drugpo.2015.07.004.Peer-Reviewed Original ResearchConceptsFibrosis progression rateHepatocellular carcinomaDisease progressionIncidence rateProgression rateHepatitis C virus disease progressionStage-specific fibrosis progression ratesPrevious injection drug useChronic HCV infectionPrognosis Studies toolPooled incidence rateInjection drug useDisease progression rateBurden of diseaseStudy inclusion criteriaNew drug regimensPeriod of infectiousnessRandom-effects modelMETAVIR unitsHCV infectionAdvanced fibrosisDrug regimensHCV preventionStage F3Inclusion criteria
2012
Randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with advanced urothelial carcinoma (UC).
Grivas P, Nanus D, Stadler W, Daignault S, Dreicer R, Kohli M, Petrylak D, Vaughn D, Bylow K, Belldegrun A, Sottnik J, Keller E, Smith D, Hussain M. Randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with advanced urothelial carcinoma (UC). Journal Of Clinical Oncology 2012, 30: 265-265. DOI: 10.1200/jco.2012.30.5_suppl.265.Peer-Reviewed Original ResearchOpen-label sunitinibAdvanced urothelial carcinomaUrothelial carcinomaMaintenance sunitinibProgression rateResponse rateMedian age 69 yearsRandomized phase II trialAdequate organ functionECOG PS 0ECOG PS 1Objective response rateCycles of chemotherapyVEGF/Age 69 yearsPhase II trialSerum level changesProgression of UCMedian TTPSecondary endpointsStable diseaseII trialOral sunitinibPS 0Complete response
2010
Prediction of progression‐free survival in patients presenting with hepatocellular carcinoma within the Milan criteria
De Giorgio M, Vezzoli S, Cohen E, Armellini E, Lucà MG, Verga G, Pinelli D, Nani R, Valsecchi MG, Antolini L, Colledan M, Fagiuoli S, Strazzabosco M. Prediction of progression‐free survival in patients presenting with hepatocellular carcinoma within the Milan criteria. Liver Transplantation 2010, 16: 503-512. PMID: 20373461, DOI: 10.1002/lt.22039.Peer-Reviewed Original ResearchConceptsMilan criteriaProgression rateHepatocellular carcinomaRisk factorsObserved progression rateT2 patientsBarcelona Clinic Liver Cancer (BCLC) algorithmEnd-Stage Liver Disease exceptionOrgan allocationTumor persistence/recurrenceStage T2 patientsT2 hepatocellular carcinomaConsecutive HCC patientsProgression-free survivalChronic liver diseasePersistence/recurrenceDistinct natural historyTreatment of choiceBCLC guidelinesMELD scoreMELD exceptionsLocal therapyTransarterial chemoembolizationLiver diseaseTumor diameter
2007
Evolution of Genotypic Resistance Algorithms and Their Impact on the Interpretation of Clinical Trials: An OPTIMA Trial Substudy
Desai S, Kyriakides T, Holodniy M, Al-Salman J, Griffith B, Kozal M. Evolution of Genotypic Resistance Algorithms and Their Impact on the Interpretation of Clinical Trials: An OPTIMA Trial Substudy. HIV Research & Clinical Practice 2007, 8: 293-302. PMID: 17956830, DOI: 10.1310/hct0805-293.Peer-Reviewed Original ResearchConceptsLong-term clinical trialsGenotypic resistance algorithmsClinical trialsDisease progressionHIV disease progression ratesHIV-1 pol sequencesHIV disease progressionDisease progression rateResistance algorithmsVirologic responseDrug comparisonsProgression rateVirtual phenotypeGenotypic algorithmsPol sequencesPatientsDrug resistanceResistance interpretationTrialsProgressionDrugsExpected ratesViral sequencesFirst eventSimilar timePrognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies
May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiébaut R, Gill J, Phillips A, Reiss P, Hogg R, Ledergerber B, D'Arminio Monforte A, Schmeisser N, Staszewski S, Egger M. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007, 21: 1185-1197. PMID: 17502729, PMCID: PMC3460385, DOI: 10.1097/qad.0b013e328133f285.Peer-Reviewed Original ResearchConceptsStart of HAARTCD4 cell countCell countHIV-1 RNA levelsHIV-1-infected patientsInitiation of HAARTTreatment-naive patientsDiagnosis of AIDSInjection drug useVirological responseHIV careNew AIDSCumulative incidenceParametric survival modelsClinical stageProspective studyRisk calculatorHAARTProgression rateTreatment changesPatientsDrug usePrognostic modelAIDSCells/
2006
Wobbly Hedgehog Syndrome in African Pygmy Hedgehogs (Atelerix spp.)
Graesser D, Spraker T, Dressen P, Garner M, Raymond J, Terwilliger G, Kim J, Madri J. Wobbly Hedgehog Syndrome in African Pygmy Hedgehogs (Atelerix spp.). Journal Of Exotic Pet Medicine 2006, 15: 59-65. DOI: 10.1053/j.jepm.2005.11.010.Peer-Reviewed Original ResearchWobbly hedgehog syndromeCentral nervous systemClinical signsNervous systemNeurogenic muscle atrophySevere neurologic signsYears of agePost-mortem examinationAfrican pygmy hedgehogNeurologic signsSpinal cordProgression rateMuscle atrophyProgressive paralysisCharacteristic histopathologyComplete paralysisMild ataxiaFamilial tendencyWhite matterAfrican hedgehogSyndromeParalysisSignsAgeOnset
2004
Gaucher disease type 1: Revised recommendations on evaluations and monitoring for adult patients
Weinreb NJ, Aggio MC, Andersson HC, Andria G, Charrow J, Clarke JT, Erikson A, Giraldo P, Goldblatt J, Hollak C, Ida H, Kaplan P, Kolodny EH, Mistry P, Pastores GM, Pires R, Prakesh-Cheng A, Rosenbloom BE, Scott CR, Sobreira E, Tylki-Szymańska A, Vellodi A, vom Dahl S, Wappner RS, Zimran A. Gaucher disease type 1: Revised recommendations on evaluations and monitoring for adult patients. Seminars In Hematology 2004, 41: 15-22. PMID: 15468046, DOI: 10.1053/j.seminhematol.2004.07.010.Peer-Reviewed Original ResearchConceptsType 1 Gaucher diseaseAdult patientsGaucher diseaseVariable progression ratesVisceral organ involvementPatient-reported qualitySF-36 surveyComplete physical examinationSignificant clinical complicationsFamily medical historyRadiologic imaging techniquesPotential permanent disabilityOrgan involvementClinical complicationsPhysical examinationMedical historySerial monitoringSkeletal involvementTherapy dosePermanent disabilityProgression rateTreatment statusTherapeutic goalsClinical heterogeneityPatients
1998
Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy
Weiss M, Rodby R, Justice A, Hricik D, Group T. Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy. Kidney International 1998, 54: 193-202. PMID: 9648079, DOI: 10.1046/j.1523-1755.1998.00982.x.Peer-Reviewed Original ResearchConceptsC-reactive proteinProtein-bound pentosidineDiabetic nephropathyInterleukin-6Serum creatinineFree pentosidineMonocyte/macrophage activationAdvanced glycation end product pentosidineBaseline disease activityDegree of proteinuriaSubgroup of patientsImmune activation responseProportional hazards methodsDisease activityInflammatory markersCreatinine levelsRenal functionDiabetes mellitusSerum levelsDiabetic complicationsProgression rateGroup trialsHazards methodsMacrophage activationNephropathy
1997
Radiographic results from the Minocycline in Rheumatoid Arthritis (MIRA) Trial.
Bluhm G, Sharp J, Tilley B, Alarcon G, Cooper S, Pillemer S, Clegg D, Heyse S, Trentham D, Neuner R, Kaplan D, Leisen J, Buckley L, Duncan H, Tuttleman M, Li S, Fowler S. Radiographic results from the Minocycline in Rheumatoid Arthritis (MIRA) Trial. The Journal Of Rheumatology 1997, 24: 1295-302. PMID: 9228128.Peer-Reviewed Original ResearchConceptsJoint space narrowingRheumatoid arthritis trialsDisease progressionArthritis trialsSpace narrowingPercentage of patientsSignificant differencesReported clinical resultsErosive jointsOral minocyclinePlacebo groupErosive diseaseFinal visitRadiographic progressionPlacebo treatmentTreat analysisRadiographic resultsFuture trialsClinical centersClinical resultsPosteroanterior filmsRadiographic changesTreatment benefitProgression rateWeek trial
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply